A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use
暂无分享,去创建一个
Luis Rodrigo | Angel Lanas | Manuel Castro | Eduardo Bajador | Á. Lanas | J. Navarro | E. Quintero | L. Rodrigo | F. Carballo | M. A. Pérez-Aisa | M. Castro | E. Saperas | J. Ponce | Enrique Quintero | Fernando Carballo | Maria Angeles Perez-Aisa | Faust Feu | Julio Ponce | Esteban Saperas | Santos Santolaria | Joaquim Balanzo | Pedro Almela | Jose M Navarro | F. Feu | P. Almela | E. Bajador | S. Santolaria | Joaquím Balanzó
[1] C. Wilcox,et al. Nonsteroidal Antiinflammatory Drugs Are Associated with Both Upper and Lower Gastrointestinal Bleeding , 1997, Digestive Diseases and Sciences.
[2] J. Reitsma,et al. Acute upper GI bleeding: did anything change? , 2003, American Journal of Gastroenterology.
[3] D. Martos,et al. Comparabilidad entre la novena y la décima revisión de la Clasificación Internacional de Enfermedades aplicada a la codificación de la causa de muerte en España , 2002 .
[4] Á. Lanas,et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection , 2005, Alimentary pharmacology & therapeutics.
[5] W. Bilker,et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications , 2002, American Journal of Gastroenterology.
[6] G. Triadafilopoulos,et al. Epidemiology of NSAID induced gastrointestinal complications. , 1999, The Journal of rheumatology. Supplement.
[7] T. Schnitzer,et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. , 2003, Gastroenterology.
[8] Lilienfeld Am,et al. Foundations of epidemiology. 2nd ed. , 1980 .
[9] J. Tijssen,et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. , 2003, The American journal of gastroenterology.
[10] B. Hirschowitz,et al. CONTROVERSIES IN THE DETECTION AND MANAGEMENT OF NONSTEROIDAL ANTIINFLAMMATORY DRUG‐INDUCED SIDE EFFECTS OF THE UPPER GASTROINTESTINAL TRACT , 1989, Arthritis and rheumatism.
[11] C. Hawkey,et al. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors , 2003, Gut.
[12] H. Magee. The Hospital Data Project: comparing hospital activity within Europe. , 2003, European journal of public health.
[13] J. Kurata,et al. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. , 1997, Journal of clinical gastroenterology.
[14] S. Morant,et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use , 1997, Alimentary pharmacology & therapeutics.
[15] M. Kimmey,et al. Appropriate use of proton pump inhibitors with traditional nonsteroidal anti‐inflammatory drugs and COX‐2 selective inhibitors , 2004, Alimentary pharmacology & therapeutics.
[16] A. Jiménez-Puente,et al. Valoración diagnóstica clínica y analítica de la trombosis venosa profunda de miembros inferiores , 2000 .
[17] A. Lilienfeld. Foundations of Epidemiology , 1980 .
[18] Lise,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[19] W. Straus,et al. Gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs. Epidemiologic and economic issues. , 2001, Gastroenterology clinics of North America.
[20] R. Moore. The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy. , 2002, Rheumatology.
[21] A. Majeed,et al. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects , 2002, Gut.
[22] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[23] Á. Lanas,et al. CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate , 2003 .
[24] M. Tramèr,et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use , 2000, Pain.
[25] J. Senior,et al. Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs , 1995, Annals of Internal Medicine.
[26] H B Devlin,et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom , 1995 .
[27] G. Harewood. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.
[28] H B Devlin,et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. , 1995, BMJ.
[29] Hirschowitz Bi,et al. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. , 1989 .
[30] M. Langman,et al. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. , 1985, British medical journal.
[31] J. Gisbert,et al. Proton pump inhibitors versus H2‐antagonists: a meta‐analysis of their efficacy in treating bleeding peptic ulcer , 2001, Alimentary pharmacology & therapeutics.
[32] Á. Lanas,et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. , 1997, Gastroenterology.